Literature DB >> 21849

Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV.

G S Giebink, J Verhoef, P K Peterson, P G Quie.   

Abstract

An assay system employing radiolabeled, heat-killed Streptococcus pneumoniae and human polymorphonuclear leukocytes was utilized to study serum pneumococcal opsonic requirements. Comparing the kinetics of phagocytosis in normal serum, heat-inactivated serum, immunoglobulin G (IgG)-deficient serum, C2-deficient serum, and magnesium dichloride ethyleneglycol-tetraacetic acid (MgEGTA)-chelated serum allowed definition of the opsonic requirements for four pneumococcal serotypes: VI XVIII, XXIII, and XXV. All four serotypes were efficiently opsonized in 10% normal serum. Only type XVIII was opsonized in heat-inactivated serum. All four were also opsonized in IgG-deficient serum but not as efficiently as in normal serum. Opsonization via the alternative pathway was diminished for all four serotypes in 10% MgEGTA-chelated and C2-deficient serum. Furthermore, by varying the concentration of MgEGTA-chelated serum, it was found that type XXV was least efficiently opsonized via the alternative pathway. The quantitative nature of this assay system will permit measurement of bacterial and host factors that may contribute to host susceptibility to pneumococcal infection.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 21849      PMCID: PMC421229          DOI: 10.1128/iai.18.2.291-297.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Pneumococcal type-associated variability in alternate complement pathway activation.

Authors:  D P Fine
Journal:  Infect Immun       Date:  1975-10       Impact factor: 3.441

2.  The role of C3 as an opsonin in the early stages of infection.

Authors:  J A Winkelstein; M R Smith; H S Shin
Journal:  Proc Soc Exp Biol Med       Date:  1975-06

3.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA.

Authors:  R AUSTRIAN; J GOLD
Journal:  Ann Intern Med       Date:  1964-05       Impact factor: 25.391

4.  Polymorphonuclear leukocyte phagocytosis: quantitation by a rapid radioactive method.

Authors:  D S Miller; S Beck
Journal:  J Lab Clin Med       Date:  1975-08

5.  Pneumococcal serum opsonizing activity in splenectomized children.

Authors:  J A Winkelstein; G H Lambert; A Swift
Journal:  J Pediatr       Date:  1975-09       Impact factor: 4.406

6.  The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus.

Authors:  J A Winkelstein; J A Bocchini; G Schiffman
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

7.  Capsulation of pneumococcus with soluble cell wall-like polysaccharide. II. Nonidentity of cell wall and soluble cell wall-like polysaccharides derived from the same and from different pneumococcal strains.

Authors:  G Schiffman; D L Bornstein; R Austrian
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

Review 8.  Opsonins: their function, identity, and clinical significance.

Authors:  J A Winkelstein
Journal:  J Pediatr       Date:  1973-05       Impact factor: 4.406

9.  Reactions between certain strains of pneumococci and Fc of IgG.

Authors:  C G Stephens; W P Reed; G Kronvall; R C Williams
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

10.  Pneumococcal pneumonia: capsular polysaccharide antigenemia and antibody responses.

Authors:  J D Coonrod; D P Drennan
Journal:  Ann Intern Med       Date:  1976-03       Impact factor: 25.391

View more
  34 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

2.  Quantitation of the third component of human complement attached to the surface of opsonized bacteria: opsonin-deficient sera and phagocytosis-resistant strains.

Authors:  H A Verbrugh; W C van Dijk; M E van Erne; R Peters; P K Peterson; J Verhoef
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

3.  The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response.

Authors:  Beza Seyoum; Masahide Yano; Liise-anne Pirofski
Journal:  Vaccine       Date:  2011-08-22       Impact factor: 3.641

4.  Two DHH subfamily 1 proteins contribute to pneumococcal virulence and confer protection against pneumococcal disease.

Authors:  L E Cron; K Stol; P Burghout; S van Selm; E R Simonetti; H J Bootsma; P W M Hermans
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

5.  Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults.

Authors:  J E Lortan; A S Kaniuk; M A Monteil
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

6.  Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae.

Authors:  T Kelly; J P Dillard; J Yother
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  Opsonization of various capsular (K) E. coli by the alternative complement pathway.

Authors:  P Stevens; L S Young; S Adamu
Journal:  Immunology       Date:  1983-11       Impact factor: 7.397

8.  Alterations in serum opsonic activity and complement levels in pneumococcal disease.

Authors:  G S Giebink; T H Dee; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

9.  Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies.

Authors:  W T Jansen; J Gootjes; M Zelle; D V Madore; J Verhoef; H Snippe; A F Verheul
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

10.  Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae.

Authors:  D S Chudwin; S G Artrip; A Korenblit; G Schiffman; S Rao
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.